| Latest Forum Topics / QT Vascular |
|
|
QT appoints banker to look for buyer!
|
|||||
|
ahlam86
Senior |
23-Mar-2016 16:26
|
||||
|
x 0
x 0 Alert Admin |
wake up liao ah |
||||
| Useful To Me Not Useful To Me | |||||
|
sheerluck
Supreme |
22-Mar-2016 19:59
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
Willing or lan lan?  Who knows?
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
doufei
Veteran |
22-Mar-2016 19:49
|
||||
|
x 0
x 0 Alert Admin |
Since there are investors willing to pump in money, that mean they see value in QT. Who knows QT might become like Sino Grandness one day. 苦 尽 甘 来
|
||||
| Useful To Me Not Useful To Me | |||||
|
sheerluck
Supreme |
22-Mar-2016 18:17
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
See my arguement for conversion.  We can expect issurance of CB or some sort of fund raise as a quarterly activity for QTV.  Poor QTV.  Want to die cannot.  Want to fly also cannot.  Lame duck.
|
||||
| Useful To Me Not Useful To Me | |||||
|
ahlam86
Senior |
22-Mar-2016 18:01
|
||||
|
x 0
x 0 Alert Admin |
some convertible bond news finally   http://infopub.sgx.com/FileOpen/SGX%20Announcement%20-%20CB%20Conversion.ashx?App=Announcement& FileID=394851   |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Demostation
Supreme |
21-Mar-2016 17:26
|
||||
|
x 0
x 0 Alert Admin |
May shoot back above 12 cents in a couple of days or two weeks. Lol
|
||||
| Useful To Me Not Useful To Me | |||||
|
ahlam86
Senior |
21-Mar-2016 17:17
|
||||
|
x 1
x 0 Alert Admin |
Closed flat today. Not bad |
||||
| Useful To Me Not Useful To Me | |||||
|
sheerluck
Supreme |
21-Mar-2016 10:37
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
Hopeless coy.  CEO and mgmt spending so much time and investors money to fight legal case.  Resources is finite.  So when more time and $$$ are spent on legal case, less time and $$$ are spent on R& D and FDA approval. FDA is still far away.  M& A wouldnt happened until appeal case got more clarity.  Cashflow problem continues to haunt them until they go into the grave. From now till then, loads of chance for price to tank and pick up cheap.  Looking at entry with siginificant discount from current price.
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
PPfander
Member |
21-Mar-2016 08:26
|
||||
|
x 0
x 0 Alert Admin |
No news on FDA approval on new products or US case clear yet. I think it need some booster to push up the share price. Hoping news of M& A soon. Good luck to all QT shareholders.
|
||||
| Useful To Me Not Useful To Me | |||||
|
doufei
Veteran |
19-Mar-2016 23:24
|
||||
|
x 0
x 0 Alert Admin |
Medical stocks in play. QT gona chiong up soon? | ||||
| Useful To Me Not Useful To Me | |||||
|
dc16888
Master |
17-Mar-2016 22:14
|
||||
|
x 0
x 0 Alert Admin |
jump 5.9% |
||||
| Useful To Me Not Useful To Me | |||||
|
Polarbear55
Senior |
09-Mar-2016 22:00
|
||||
|
x 0
x 0 Alert Admin |
This pure speculation will turn to pure ecstasy! Watch pure entertainment tmw! 😱 | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
sheerluck
Supreme |
29-Feb-2016 22:52
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
M& A is pure speculation.  From waht I gathered so far.  NO WHERE NEAR.  If within the next three month you see more fund raise, you know that is the case.  Now it is just a pure BB play.  So play with caution!
|
||||
| Useful To Me Not Useful To Me | |||||
|
Polarbear55
Senior |
29-Feb-2016 22:40
|
||||
|
x 0
x 0 Alert Admin |
This baby no point looking at p&l any longer..it's pure M&A play now. Tmw if bb say fly, it will fly past 0.12 to 0.14!!😃 | ||||
| Useful To Me Not Useful To Me | |||||
|
sheerluck
Supreme |
29-Feb-2016 21:27
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
Putting aside all the known negatives, if I looked deeper, the results are actually......not as bad as I thought it will be.  Comparing units sale between this and last quarter was an 25% increase athough the sale volume is still low. The main problem is with cashflow.  Cashflow from operation used up US$7mil in Q4 alone.  So can the CB invesetors don' t release the 2nd tranche then?  They have to.  No choice.  If not QTV close shop, they get nothing back!  Can QTV pay the CB investors the interests?  Yes! Using the CB investors own money.  Can the QTV pay back the loan?  No!  So how can CB investors recoup their poor investment?  Already converted their bond to shares.  So these are now liquid. Recently, they have expanded their CB by another US$6.06million so they are safe for Q1 now.  QTV is really living quarter by quarter now.  QTV really needs some huge credit line but who will grant them this safety net given their lackluster sale volume and court case? DYDD.
|
||||
| Useful To Me Not Useful To Me | |||||
|
moron101
Supreme |
29-Feb-2016 19:08
|
||||
|
x 0
x 0 Alert Admin |
Poor result announced. Net loss $53M for FY. | ||||
| Useful To Me Not Useful To Me | |||||
|
sheerluck
Supreme |
25-Feb-2016 15:17
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
Only 15cts????  You look down on QTV?
|
||||
| Useful To Me Not Useful To Me | |||||
|
johnng
Supreme |
25-Feb-2016 15:11
|
||||
|
x 0
x 0 Alert Admin |
Takeover 15cent will be good... |
||||
| Useful To Me Not Useful To Me | |||||
|
sheerluck
Supreme |
25-Feb-2016 14:46
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
Not surprising.  For those who bought ard 9cts, 20% profit is tempting but maybe also want to offload to greater fools before scary Q4 results shattered their plan.
|
||||
| Useful To Me Not Useful To Me | |||||
|
ahlam86
Senior |
25-Feb-2016 14:43
|
||||
|
x 0
x 0 Alert Admin |
Law360, New York (February 17, 2016, 11:48 PM ET) -- TriReme Medical Inc. and two other companies urged the Federal Circuit on Tuesday to reverse a Delaware federal court' s interpretation of state law that led to their being on the hook for $20 million in past and future profits to AngioScore Inc. over one of its founder' s heart catheter designs. The lower court erred in reaching the determination that TriReme, Quattro Vascular PTE Ltd., QT Vascular Ltd. and Eitan Konstantino should pay the money after concluding that Konstantino breached his fiduciary duty by not first offering the rights to the balloon catheter he co-invented to AngioScore, according to the defendants&rsquo brief. The lower court agreed with AngioScore&rsquo s assertion that under the state&rsquo s &ldquo corporate opportunity doctrine,&rdquo Konstantino, a founder of AngioScore who was serving as an unpaid outside director for the company, was obligated to offer the company the rights to the invention, the brief reads. But the holding misinterpreted the doctrine, which is meant for instances when fiduciaries divert to themselves business opportunities brought forward by third parties, according to the defendant companies. The holding also conflicts with federal patent laws that bar employers from claiming the rights to conceptions that a person has invented on their own, in situations where there is no written agreement between the parties saying otherwise, according to the brief. &ldquo The doctrine has never applied, and indeed makes no sense, when the purported opportunity is the director&rsquo s own invention,&rdquo the brief reads. AngioScore sued TriReme, Quattro Vascular PTE Ltd., QT Vascular Ltd. and Konstantino in 2012, claiming that while he was still on the company board, Konstantino began developing a competing product, the Chocolate catheter, with TriReme. After a bench trial held in April, U.S. District Judge Yvonne Gonzalez Rogers found that Konstantino breached his fiduciary duty to AngioScore and hid what he was doing. Judge Gonzalez Rogers ordered Konstantino to disgorge any profits he earned from the breach and told the defendants to pay a total of $20 million in past and future lost profits, according to the order. However, that trial didn&rsquo t address AngioScore&rsquo s patent infringement claims. In September, a jury held that the Chocolate catheter did not infringe AngioScore&rsquo s U.S. Patent Number 7,691,119, according to the verdict. Counsel for the parties could not be reached on Wednesday for comment. AngioScore is represented by Robert P. Feldman, William Adams and Peter J. Armenio of Quinn Emanuel Urquhart & Sullivan LLP. The defendants are represented by Lisa S. Blatt and David A. Caine of Arnold & Porter LLP and David S. Steuer, Steven D. Guggenheim and Dylan J. Liddiard of Wilson Sonsini Goodrich & Rosati PC. The case is AngioScore Inc. v. TriReme Medical LLC et al., case number 16-1126, in the U.S. Court of Appeals for the Federal Circuit. --Additional reporting by Beth Winegarner and Daniel Langhorne. Editing by Philip Shea.
|
||||
| Useful To Me Not Useful To Me | |||||

